全文获取类型
收费全文 | 21518篇 |
免费 | 1673篇 |
国内免费 | 76篇 |
专业分类
耳鼻咽喉 | 199篇 |
儿科学 | 691篇 |
妇产科学 | 595篇 |
基础医学 | 3207篇 |
口腔科学 | 311篇 |
临床医学 | 2439篇 |
内科学 | 4299篇 |
皮肤病学 | 608篇 |
神经病学 | 2088篇 |
特种医学 | 670篇 |
外国民族医学 | 26篇 |
外科学 | 2154篇 |
综合类 | 187篇 |
一般理论 | 21篇 |
预防医学 | 2317篇 |
眼科学 | 383篇 |
药学 | 1301篇 |
中国医学 | 37篇 |
肿瘤学 | 1734篇 |
出版年
2024年 | 42篇 |
2023年 | 284篇 |
2022年 | 523篇 |
2021年 | 1000篇 |
2020年 | 608篇 |
2019年 | 812篇 |
2018年 | 889篇 |
2017年 | 668篇 |
2016年 | 750篇 |
2015年 | 761篇 |
2014年 | 951篇 |
2013年 | 1227篇 |
2012年 | 1769篇 |
2011年 | 1794篇 |
2010年 | 929篇 |
2009年 | 813篇 |
2008年 | 1256篇 |
2007年 | 1269篇 |
2006年 | 1088篇 |
2005年 | 1056篇 |
2004年 | 981篇 |
2003年 | 866篇 |
2002年 | 748篇 |
2001年 | 176篇 |
2000年 | 155篇 |
1999年 | 166篇 |
1998年 | 151篇 |
1997年 | 127篇 |
1996年 | 93篇 |
1995年 | 99篇 |
1994年 | 80篇 |
1993年 | 69篇 |
1992年 | 96篇 |
1991年 | 91篇 |
1990年 | 79篇 |
1989年 | 72篇 |
1988年 | 44篇 |
1987年 | 68篇 |
1986年 | 64篇 |
1985年 | 54篇 |
1984年 | 49篇 |
1983年 | 41篇 |
1982年 | 28篇 |
1981年 | 39篇 |
1980年 | 27篇 |
1979年 | 25篇 |
1978年 | 30篇 |
1974年 | 28篇 |
1973年 | 23篇 |
1971年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Sybille Rousseau Matthieu Peycelon Céline Grosos Valeska Bidault Anna Poupalou Garance Martin Éric Dobremez Luke Harper Claire Raquillet Alexis Arnaud Emmanuel Sapin Aurélien Scalabre Philippe Buisson Guillaume Levard Isabelle Pommepuy Maguelonne Pons Laurent Fourcade Quentin Ballouhey 《Journal of pediatric surgery》2021,56(2):332-336
IntroductionFibroepithelial polyps (FEP) of the lower urinary tract are relatively common in adults but rare in children, with fewer than 250 cases reported in the literature to date.ObjectiveThe aim of this study was to address the experience of FEP management in children.Study designA retrospective multicenter review was undertaken in children with defined FEP of the lower urinary tract managed between 2008 and 2018. The data at 18 pediatric surgery centers were collected. Their demographic, radiological, surgical, and pathological information were reviewed.ResultsA total of 33 children (26 boys; 7 girls) were treated for FEP of the lower urinary tract at 13 centers. The most common presentation was urinary outflow as hematuria (41%), acute urinary retention (25%), dysuria (19%), or urinary infections (28%). A prenatal diagnosis was made for three patients with hydronephrosis. Almost all of the children (94%) underwent ultrasound imaging of the urinary tract as the first diagnostic examination, 23 (70%) of them also either had an MRI (15%), cystourethrography (25%), computerized tomography (6%), or cystoscopy (45%). Two of these children (6%) had a biopsy prior to the surgery. The median preoperative delay was 7.52 (range: 1–48) months. Most of the patients were treated endoscopically, although four (12.1%) had open surgery and two (6.1%) had an additional incision for specimen extraction. The median hospital stay was 1.5 (range: 1–10) days. There were no recurrences and no complications after a median follow-up of 13 (range: 1–34) months.DiscussionThe main limitation of our study is the retrospective design, although it is the largest one for this pathology.ConclusionThis series supports sonography as the most suitable diagnosis tool before endoscopy to confirm the diagnosis and to perform the resection for most FEP in children. This report confirms the recognized benign nature in the absence of recurrences.Level of EvidenceLevel V. 相似文献
102.
Herremans Kelly M. Cribbin Morgan P. Riner Andrea N. Neal Dan W. Hollen Tracy L. Clevenger Pamela Munoz Derly Blewett Shannon Giap Fantine Okunieff Paul G. Mendenhall Nancy P. Bradley Julie A. Mendenhall William M. Mailhot-Vega Raymond B. Brooks Eric Daily Karen C. Heldermon Coy D. Marshall Julia K. Hanna Mariam W. Leyngold Mark M. Virk Sarah S. Shaw Christiana M. Spiguel Lisa R. 《Annals of surgical oncology》2021,28(10):5775-5787
Annals of Surgical Oncology - Breast cancer-related lymphedema (BCRL) is a source of postoperative morbidity for breast cancer survivors. Lymphatic microsurgical preventive healing approach... 相似文献
103.
104.
105.
James F. Markmann Michael R. Rickels Thomas L. Eggerman Nancy D. Bridges David E. Lafontant Julie Qidwai Eric Foster William R. Clarke Malek Kamoun Rodolfo Alejandro Melena D. Bellin Kathryn Chaloner Christine W. Czarniecki Julia S. Goldstein Bernhard J. Hering Lawrence G. Hunsicker Dixon B. Kaufman Olle Korsgren Christian P. Larsen Xunrong Luo Ali Naji José Oberholzer Andrew M. Posselt Camillo Ricordi Peter A. Senior A. M. James Shapiro Peter G. Stock Nicole A. Turgeon 《American journal of transplantation》2021,21(4):1477-1492
106.
Cecilia Nakid-Cordero Sylvain Choquet Nicolas Gauthier Noureddine Balegroune Nadine Tarantino Véronique Morel Nadia Arzouk Sonia Burrel Géraldine Rousseau Frédéric Charlotte Martin Larsen Vincent Vieillard Brigitte Autran Véronique Leblond Amélie Guihot for the K-VIROGREF Study Group 《American journal of transplantation》2021,21(8):2846-2863
EBV-positive and EBV-negative posttransplant lymphoproliferative disorders (PTLDs) arise in different immunovirological contexts and might have distinct pathophysiologies. To examine this hypothesis, we conducted a multicentric prospective study with 56 EBV-positive and 39 EBV-negative PTLD patients of the K-VIROGREF cohort, recruited at PTLD diagnosis and before treatment (2013–2019), and compared them to PTLD-free Transplant Controls (TC, n = 21). We measured absolute lymphocyte counts (n = 108), analyzed NK- and T cell phenotypes (n = 49 and 94), and performed EBV-specific functional assays (n = 16 and 42) by multiparameter flow cytometry and ELISpot-IFNγ assays (n = 50). EBV-negative PTLD patients, NK cells overexpressed Tim-3; the 2-year progression-free survival (PFS) was poorer in patients with a CD4 lymphopenia (CD4+<300 cells/mm3, p < .001). EBV-positive PTLD patients presented a profound NK-cell lymphopenia (median = 60 cells/mm3) and a high proportion of NK cells expressing PD-1 (vs. TC, p = .029) and apoptosis markers (vs. TC, p < .001). EBV-specific T cells of EBV-positive PTLD patients circulated in low proportions, showed immune exhaustion (p = .013 vs. TC) and poorly recognized the N-terminal portion of EBNA-3A viral protein. Altogether, this broad comparison of EBV-positive and EBV-negative PTLDs highlight distinct patterns of immunopathological mechanisms between these two diseases and provide new clues for immunotherapeutic strategies and PTLD prognosis. 相似文献
107.
Aránzazu Caballero-Marcos Magdalena Salcedo Roberto Alonso-Fernández Manuel Rodríguez-Perálvarez María Olmedo Javier Graus Morales Valentín Cuervas-Mons Alba Cachero Carmelo Loinaz-Segurola Mercedes Iñarrairaegui Lluís Castells Sonia Pascual Carmen Vinaixa-Aunés Rocío González-Grande Alejandra Otero Santiago Tomé Javier Tejedor-Tejada José María Álamo-Martínez Luisa González-Diéguez Flor Nogueras-Lopez Gerardo Blanco-Fernández Gema Muñoz-Bartolo Francisco Javier Bustamante Emilio Fábrega Mario Romero-Cristóbal Rosa Martin-Mateos Julia Del Rio-Izquierdo Ana Arias-Milla Laura Calatayud Alberto A. Marcacuzco-Quinto Víctor Fernández-Alonso Concepción Gómez-Gavara Jordi Colmenero Patricia Muñoz José A. Pons the Spanish Society of Liver Transplantation 《American journal of transplantation》2021,21(8):2876-2884
The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID-19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti-SARS-CoV-2 antibodies and more pronounced antibody levels decline. 相似文献
108.
Wagner Abram L. Porth Julia M. Wu Zhenke Boulton Matthew L. Finlay Jessica M. Kobayashi Lindsay C. 《Journal of community health》2022,47(3):408-415
Journal of Community Health - It is important to distinguish between apprehensions that lead to vaccine rejection and those that do not. In this study, we (1) identifed latent classes of... 相似文献
109.
110.